Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis

Pharmacological Research

Volumn 42, Issue 1, 2000, Pages 39-50

  Grandjean, E M ^a   Berthet, P H ^b   Ruffmann, R ^c   Leuenberger, Ph ^d  

^a Phidalsa Institute for Clinical I   (Switzerland)

^b Biometrix SA   (Switzerland)

^c Inpharzam/Zambon Group   (Switzerland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Acetylcysteine; Chronic bronchitis; Cost effectiveness; Exacerbations

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID;

ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DRUG COST; HUMAN; HUMAN TISSUE; LUNG FUNCTION TEST; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; SWITZERLAND; WINTER;

EID: 0033849631     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1999.0647     Document Type: Article

References (37)

1. N-Acetylcysteine: Pharmacological considerations and experimental and clinical applications
2. Acute infective exacerbations of chronic bronchitis
3. Acute exacerbations of chronic bronchitis: An international comparison
4. An interview study to estimate prevalence of asthma and chronic bronchitis. The obstructive lung disease in Northern Sweden study
5. Determinants of chronic bronchitis prevalence in an elderly sample from South-West of France
6. Prevalence and treatment of chronic airways obstruction in adults over the age of 45
7. Etude suisse sur la pollution de l'air et les maladies respiratoires chez l'adulte
8. Incidence and direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland
9. The future of pharmacoeconomics: Bridging science and practice
10. The future of pharmacoeconomics: A commentary
11. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care
12. Sensitivity analysis in economic evaluation: A review of published studies
13. Trying to do better than average: A commentary on 'statistical inference for cost-effectiveness ratios'
14. Pharmacoeconomics: Basic concepts and terminology
15. Definition and classification of chronic bronchitis for clinical and epidemiological purposes
16. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis
17. Long-term oral acetylcysteine in chronic bronchitis
18. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis
19. Efficacy and tolerability of Oral Acetylcysteine in Chronic Bronchitis
20. Oral N-acetylcysteine and exacerbations rates in patients with chronic bronchitis
21. Langzeittherapie mit Acetylcystein Re-tard-Tabletten bei Patienten mit chronischer Bronchitis
22. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis
23. Reduction in days of illness after long-term treatment with N-acetylcy-steine controlled-release tablets in patients with chronic bronchitis
24. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis
25. Meta-analysis
26. Pharmacoeconomic evaluations and clinical trials
27. Cost of relapse in schizophrenia
28. Traitement immediat ou differe de l'otite moyenne aigue? Une analyse medico-economique
29. Patterns of drug taking in patients with chronic airflow obstruction
30. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group
31. A nebulizer chronolog to monitor compliance with inhaler use
32. Infections respiratoires recidivantes du sujet atteint de bronchite chronique obstructive: Prise en charge medicale et couts
33. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: Four-year follow-up randomized controlled study
34. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease
35. Preventive treatment of chronic bronchitis: A metaanalysis of clinical trials with a bacterial extract (OM-85 BV) and a cost-effectiveness analysis